Communiqués Absci Corporation

Actions

ABSI

US00091E1091

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 28/09/2026			Varia. 5j.	Varia. 1 janv.
9,490 ^USD	-2,57%		-1,66%	+171,92%

24/09	Absci Corporation annonce les détails préliminaires de l’essai de phase 2 STORYLINE™ évaluant l’anticorps ABS-201 conçu par intelligence artificielle contre l’endométriose	CI
24/09	Absci prévoit de lancer à la mi-2027 un essai de phase intermédiaire d’ABS-201 contre l’endométriose	MT

Communiqués

24/09	Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis	GL
01/09	Absci to Participate in Upcoming Investor Conferences	GL
11/08	Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results	GL
24/07	A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed	AQ
14/07	Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026	GL
24/06	Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors	GL
24/06	Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)	GL
16/06	The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It	AQ
10/06	OpenFold Consortium Adds Eleven New Members as Momentum Builds for Open AI Infrastructure in Biology and Drug Discovery	AQ
20/05	Absci to Participate in Upcoming Investor Conferences	GL
08/05	Absci : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results	GL
07/05	Absci : Corporate Presentation, May 2026	PU
05/05	Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
23/04	Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026	GL
08/04	Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference	GL
24/03	Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results	GL
24/03	Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic	GL
24/03	Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic	AQ
06/03	Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
03/03	Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer	GL
24/02	Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026	GL
17/02	Absci to Participate in Upcoming Investor Conferences	GL
16/12	Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference	GL
16/12	Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference	AQ